GT Biopharma Files Prospectus Related To The Offer Up To 13,502,835 Shares Of Common Stock By Selling Stockholders
-SEC Filing
Stocks · News reference
EXCLUSIVE: GT Biopharma Achieves Development Milestone for Human Trial for Novel Blood Cancer Therapy
GT Biopharma secures FDA IND clearance for GTB-5550, advancing its TriKE therapy into Phase 1 clinical trials for multiple myeloma.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — GT Biopharma, Inc. (GTBP)
Filed: 2026-09-25 AccNo: 0001493152-26-044309 Size: 204 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
GT Biopharma shares are trading lower. The company announced IND clearance from the FDA for GTB-5550 in multiple myeloma.
GT Biopharma Announces IND Clearance From FDA For GTB-5550 In Multiple Myeloma
FDA clearance of a new IND for GTB-5550 in multiple myeloma (MM) under an investigator sponsored trial (IST) protocolInitiation of Phase 1 trial in MM patients contingent upon timing and receipt of non-dilutive grant